scholarly journals COVID-19 International Collaborative Research by the Health Insurance Review and Assessment Service Using Its Nationwide Real-world Data: Database, Outcomes, and Implications

2021 ◽  
Vol 54 (1) ◽  
pp. 8-16
Author(s):  
Yeunsook Rho ◽  
Do Yeon Cho ◽  
Yejin Son ◽  
Yu Jin Lee ◽  
Ji Woo Kim ◽  
...  
Keyword(s):  
Health Insurance ◽  
Real World ◽  
Collaborative Research ◽  
Real World Data ◽  
World Data ◽  
International Collaborative ◽  
International Collaborative Research

Lessons learned from the reimbursement policy for immune checkpoint inhibitors and real-world data collection in Taiwan

2020 ◽  
pp. 1-5
Author(s):  
Li Ying Huang ◽  
Churn-Shiouh Gau
Keyword(s):  
Health Insurance ◽  
National Health Insurance ◽  
National Health ◽  
Real World ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Reimbursement Policy ◽  
Real World Data ◽  
World Data

Abstract This paper describes the reimbursement policy for immune checkpoint inhibitors in Taiwan and provides a perspective to improve the quality, consistency, and transparency of decision making. Global trends for cancer treatment have shifted from chemotherapies to targeted therapies and immuno-oncology (IO) medicine, leading to significant increases in treatment costs. To enhance the accessibility of advanced therapy, the Taiwan National Health Insurance Administration announced two pathways for high-cost medicine: the managed entry agreement and a set of general rules of reimbursement submission for high-cost drugs. To further manage the financial burden on Taiwan's national health insurance system, the policy makers introduced novel inhibitory drugs for cancer immune checkpoints, subject to a maximum annual budget of NT$800 million (≈US$26.7 million). In April 2019, a national registry was established for patients undergoing cancer immunotherapy. Clinical characteristics, treatment duration, toxicity, and the outcome of the postcheckpoint inhibitor treatments were recorded. By analyzing real-world data, we assess the therapeutic effect of IO treatment in Taiwanese patients, thereby enabling payers to adjust payment regulations and rules for reimbursement. The Health Technology Assessment Team plays an important role in drawing upon the evidence to support policy making. Under an implemented cost-management mechanism, Taiwan's high-cost drug policy has enabled patients to access new medicines and maximized patient benefits.

Sign in / Sign up

Export Citation Format

Share Document